Member Info for chester18

In that Proactive interview with David Ebsworth ( Monday 2nd December) he definitely says they were hoping to report before the end of the year.
So he's not going to say that if there was 'no chance' of it happening.

Chester.

It actually tells us two things for sure,

1) That there is no sensitive news imminent.

2 ) That Martin Diggle sees 5.2p a share not so much a good deal but a 'Steal Deal'.

.....IMHO......

Chester.

Howie

Have you just got a bad case of Share Euphoria Tourette's......ha ha

Chester

A bit more activity and interest today but not exactly a stampede.

But I'm still looking forward with anticipation to an RNS, hopefully soon.

Chester.

The Chair, David Ebsworth also said that they were "hopeful" that they would be able to report the trial data by the end of the year.
Meaning it's not guaranteed in the next two weeks but, how he said it, they must be trying their best to get it out as promised 'by the end of 2019'.

Let's hope it's a proper Christmas Cracker.

Chester.

Watched the Proactive interview, if we were able to just trust what we're being told, then we would have to believe that VRP is heading for a substantial positive re-rate.
It is how things are said that's the difficulty. Obviously he needed to be positive in what he said but also use language that hints at but does not confirm how good the data actually is. As I've said previously the next announcement on trial data is critical..
Due to JAK signing up for £250M options just recently does push me into the "data is going to be good" camp.

Chester.

Morning Howie123

If you are so confident why have we not seen at least one large buy from your goodself this morning.

On checking your past posts I can see you were the same as me and held a big chunk of shares at a high price. So if your message could be believed I would have thought you would have definitely topped up this morning to reduce your average.

So I'm left very confused by your very rampy posts as they don't fit with your normal sentiments concerning VRP.

Chester.

Hi Helu0104

From what we have been told it looks like the company could see the sales potential growth early on in 2019.
So I would say that a company as well run as Tissue Regenix would start to employ and train their future staff as early as possible. My guess is that it's an on going task and will be governed by the increase in manufacturing plant but especially with TRX it will be laboratory space and clean rooms.

I would love a tour around their manufacturing facilities in Texas as it would answer many of my questions.

All the best,
Chester.

Just as an example of how this could play out. I bought Ocado shares very early in their existence I think I paid £2.20 / share . As they built their business the length it was taking and the cash burn drove the price down to around 69p. As the company developed and it got back around £1.80, I decided it was time to leave and 5 years later they were £13.50 / share.

I honestly believe that Tissue Regenix, once past these growth pains, could be a £5 share company. So it's pretty crap having to see the daily misdemeanors while we're stuck at 1p but that's not the issue, it's where will the price be once they get to breakeven and beyond. Also this is not a start up company and we need trial data this is a growing company in a massive market that's growing year on year. The potential for us private investors is well worth the risk of 1p a share.

Chester.

Hi StuoftheToon

I've just looked back at the RNS 4th June.
Annual Report year ending 31st Dec 2018.

There is this comment.......

"We have continued to develop our commercial partnerships and have a strong pipeline of both new product launches and product line extensions, which are expected in the near term. We remain committed to optimising operations and have introduced new shift patterns to meet increasing demand. We are optimistic these benefits will continue into the future".

So new shift patterns already in place prior to June this year which means that the company were well ahead of the game.
Probably started training new staff last March or April. Just guessing but would make sense if they had already implimented more production shifts in June.

Chester.

Hi B2HS2L

You raise some very good points.
TRX have said that they have enough cash to run the company until March 2020. They probably face some large bill's to pay at that time that are related to all the spending on re-fitting the works and the new kit they have bought.
MidCap want to make sure their investment money is going to be safe before they jump aboard the Tissue Regenix train. The agreed loan is not just cash + interest its cash for new shares at an agreed price. I'm not fully aware of all the details but if you look back through the RNS's you will find the announcement of the load deal and all the related detail.

So if MidCap decide that in their opinion that their loan / investment money will not produce a return they will say no. But TRX has the nearly three months to show that the future is going as planned. The day that MidCap sign that loan off and hand over the cash is the same day this current share price will like the biggest give a way ever.

Let me know if that makes sense to you and also let me know if you have have a different take on the possible events going forward.

All the best

Chester.

The SP is stuck between 1p and 1.15p.
The 10% traders just see no news as ideal to keep buying in around the 1p mark and sell just it clears 1.1 - 1.2p. Added to this the MM's do mix the buy / sell by continually changing the spread.
Still it leaves the price in the bargain range if you want to hold for 12 months.

My thoughts are that even in the worst, worst case scenario the company, their order book and all the IP is worth a lot more than the current share price. I've been in this share for over 5 years so have followed the progress .
Woodford pumped a lot of money into TRX , probably the reason they could buy CellRight Technology's.

We are now waiting for a clear indication from the company that the last quarter 2019 has been a success. That's not going to happen until mid January. The only other game changer is if they announce a new product line or a new deal .

All the best

Chester.

There is no point worrying if there will be or won't be the need to raise more funds. The issue here is can the company finance the growth in their sales until they hit break even and beyond. Its the kind of problem many expanding companies have to deal with.

The deal with MidCap can only be realised if MidCap are happy that TRX has proven that the loan will result in eventual profits and not more debt that will need more finance. So the company has to demonstrate it has control of the situation and is not just buying sales by offering large discounts or obscene sales commissions.

But TRX can also just go back to the market and raise funds through the issuing of more shares and the success of that will depend on the share price at that time.
The key here at this moment in time is this question :

"Has the increase in manufacturing and the pulling of double shifts resulted in a marked increase in sales turnover during the final quarter of 2019".

If it has then they can report the hell out of it and the SP will start to recover rapidly. They can then report January's figures in Feb and February's figures in March. With the sole aim of getting the SP as high as possible to then raise some capital.

This is a "risk to very high reward" situation but the ace card is that Tissue Regenix products are in high demand and very high regard with their customers.

My opinion of course and please do your own research.

Chester.

Scancell may have been able to foster a special deal for Keytruda with Nottingham NHS due to their joint relationships with Notts University. Trying to get other cash strapped NHS authorities to stump up for Keytruda may be to big an ask. This is where big pharma with their deep pockets win over small independent biotects every time.

I would think they are trying their level best to open up some more uk sites but considering the current political situation in might be the wrong time. We can but hope.

We need the FDA to pull their finger out....

Chester.

Just listened to the whole 42 mins of the recent webcast. Very strong presentation which gives me confidence to say that RENE are world leaders in their field. The succesful outcome of using stem cells could one day be akin to the discovery of antibiotics.

A positive CTX programme will be life changing for millions of people where having a stroke will no longer mean being given no hope of any improvements .
Your probably correct in saying 2 to 3 years before we know for certain but I would think that the share price will grow steadily as we move towards more data and some further deals.

For all long term holders like myself is wish you every success in 2020 and for any potential newbies all I can say is grab a few shares as they won't always be this cheap.

Chester.

Excellent RNS, Reneuron are set for a very successful 2020 and beyond.

Chester.

Hi Si

I've notice Freddieboy now posts on VAL
(Valrix)..

Chester.

I'm posting this again because either there is an offer to buy the company by whomever has been buying all the shares or we need to here from the company.

Having been here a long time I've seen the whole story play out.
As I have said previously, the BOD have been very aggressive at pushing this company forward. Their in the Elbow your way into a market phase and it takes a lot of cash to infiltrate the medical sector, plus there doing a great job.
Your all correct when you say they need more capital and that currently they are ripe for being bought out.
My opinion is that the big next driving force here will be the last quarter sales figures. They need to show that the extra manufacturing which is mainly 24 hours double shifts has continued the upward momentum of the gross value of their sales. I'm not to worried about the lost of profit due to the higher wage bill its keeping the growth momentum that is critical.
So if you are looking for a quick buck come back end January if you want to be part of the ride back north of 5p, get a foothold and stay put. Probably 12 months will see this back in a financially stable place.

As I will always say, do your own research and only risk what you can afford to lose.

Chester.

Just to clarify those two £1M trades were timed at 10.05am when the buy price was 1.06p so definitely they were sells.
Always check the time stamp the colour is irrelevant.

Chester

Having been here a long time I've seen the whole story play out.
As I have said previously, the BOD have been very aggressive at pushing this company forward. Their in the Elbow your way into a market phase and it takes a lot of cash to infiltrate the medical sector, plus there doing a great job.
Your all correct when you say they need more capital and that currently they are ripe for being bought out.
My opinion is that the big next driving force here will be the last quarter sales figures. They need to show that the extra manufacturing which is mainly 24 hours double shifts has continued the upward momentum of the gross value of their sales. I'm not to worried about the lost of profit due to the higher wage bill its keeping the growth momentum that is critical.
So if you are looking for a quick buck come back end January if you want to be part of the ride back north of 5p, get a foothold and stay put. Probably 12 months will see this back in a financially stable place.

As I will always say, do your own research and only risk what you can afford to lose.

Chester